NCT07562724Not yet recruiting
Diet and WB-EMS Effects in Obesity
Effects of Energy-Restricted Diet and Whole-Body Electromyostimulation (WB-EMS) on Myokine-Adipokine Interaction, Appetite Regulation, and Body Composition in Obese Individuals: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 14 May 2026
Brief summary (registry, in English)
Obesity is a major global health problem associated with metabolic dysfunction, altered adipokine signaling, and impaired appetite regulation. Conventional weight loss strategies such as calorie restriction often result in compensatory physiological adaptations, including increased appetite and loss of lean body mass, which may limit long-term effectiveness. Whole-body electromyostimulation (WB-EMS) is an emerging, time-efficient intervention that induces simultaneous muscle activation and may improve metabolic health. However, the underlying molecular mechanisms, particularly the interaction between myokines and adipokines, remain insufficiently understood. This randomized controlled trial aims to investigate the effects of an energy-restricted diet combined with WB-EMS on myokine-adipokine interaction, appetite regulation, and body composition in obese individuals. Participants will be randomly assigned to either a diet-only group or a diet plus WB-EMS group for 8 weeks. Primary outcomes include changes in serum irisin levels. Secondary outcomes include myostatin, leptin, adiponectin, FGF-21, ghrelin, GLP-1, body composition parameters, and eating behavior. The findings of this study are expected to provide novel insights into the physiological and molecular effects of WB-EMS as a complementary strategy in obesity management.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 26 Apr 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 20 Jan 2027
- Lead sponsor
- Firat University
- Diseases
- Obesity
- NCT number
- NCT07562724
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 1 Sept 2026 to the primary completion date, 20 Jan 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of medications affecting body composition or appetite (e.g., corticosteroids, weight-loss drugs)
- Substance abuse, including alcohol or drug dependency
Other illness
- Known cardiovascular disease or severe chronic illness
- Uncontrolled diabetes or severe metabolic disorders
- Active malignancy or cancer treatment
- Severe renal or hepatic failure
- Acute infection or inflammatory disease
- Orthopedic conditions limiting physical activity
- Psychiatric or cognitive conditions affecting adherence to the study protocol
Other
- Presence of pacemaker or implantable cardioverter-defibrillator
- Pregnancy or breastfeeding
- Regular resistance training within the last 3 months
Who the study is looking for
- Age between 18 and 65 years
- Body mass index (BMI) ≥ 30 kg/m²
- Sedentary lifestyle (less than 2 hours of structured exercise per week)
- Willingness to participate and provide written informed consent
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dicle University Coordinator of this site? Confirm its status | Diyarbakır | Turkey (Türkiye) | Unknown status |
| Firat University Coordinator of this site? Confirm its status | Elâzığ | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.